JP6620096B2 - ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物 - Google Patents

ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物 Download PDF

Info

Publication number
JP6620096B2
JP6620096B2 JP2016540481A JP2016540481A JP6620096B2 JP 6620096 B2 JP6620096 B2 JP 6620096B2 JP 2016540481 A JP2016540481 A JP 2016540481A JP 2016540481 A JP2016540481 A JP 2016540481A JP 6620096 B2 JP6620096 B2 JP 6620096B2
Authority
JP
Japan
Prior art keywords
compound
branched
benzyloxy
dimethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016540481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501163A (ja
Inventor
ユ、サン−ク
チョン、チン−ウク
チョ、イン−クン
イム、チョン−ホ
カン、ク−ソク
キム、チン−ヨン
Original Assignee
グラセウム、インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラセウム、インコーポレーテッド filed Critical グラセウム、インコーポレーテッド
Publication of JP2017501163A publication Critical patent/JP2017501163A/ja
Application granted granted Critical
Publication of JP6620096B2 publication Critical patent/JP6620096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2016540481A 2013-12-24 2014-12-23 ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物 Active JP6620096B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20130162909 2013-12-24
KR10-2013-0162909 2013-12-24
KR1020140181951A KR102344479B1 (ko) 2013-12-24 2014-12-17 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
KR10-2014-0181951 2014-12-17
PCT/KR2014/012688 WO2015099392A1 (ko) 2013-12-24 2014-12-23 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018056783A Division JP2018135343A (ja) 2013-12-24 2018-03-23 ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物

Publications (2)

Publication Number Publication Date
JP2017501163A JP2017501163A (ja) 2017-01-12
JP6620096B2 true JP6620096B2 (ja) 2019-12-11

Family

ID=53788040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016540481A Active JP6620096B2 (ja) 2013-12-24 2014-12-23 ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物
JP2018056783A Pending JP2018135343A (ja) 2013-12-24 2018-03-23 ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018056783A Pending JP2018135343A (ja) 2013-12-24 2018-03-23 ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物

Country Status (21)

Country Link
US (1) US9783551B2 (enExample)
EP (1) EP3098224B1 (enExample)
JP (2) JP6620096B2 (enExample)
KR (1) KR102344479B1 (enExample)
CN (1) CN105849111B (enExample)
AU (1) AU2014370697B2 (enExample)
BR (1) BR112016011281B1 (enExample)
CA (1) CA2929001C (enExample)
CY (1) CY1121554T1 (enExample)
DK (1) DK3098224T3 (enExample)
ES (1) ES2718878T3 (enExample)
HR (1) HRP20190573T1 (enExample)
HU (1) HUE043902T2 (enExample)
IL (1) IL245908B (enExample)
MX (1) MX374944B (enExample)
NZ (1) NZ720328A (enExample)
PL (1) PL3098224T3 (enExample)
PT (1) PT3098224T (enExample)
SG (1) SG11201604371PA (enExample)
TW (1) TWI585093B (enExample)
WO (1) WO2015099392A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
TWI731998B (zh) 2016-06-29 2021-07-01 南韓商格雷森伍股份有限公司 光學活性吡喃並苯並吡喃基苯酚衍生物及包含其的醫藥組成物
TWI641610B (zh) * 2016-10-04 2018-11-21 南韓商格雷森伍股份有限公司 用於合成3-苯基-2,3,4,8,9,10-六氫吡喃並[2,3-f]色烯衍生物及其光學異構物的方法
TWI804600B (zh) * 2018-04-03 2023-06-11 南韓商格雷森伍股份有限公司 3-苯基-2,8-二氫吡喃[2,3-ƒ]苯并哌喃衍生物的合成方法
WO2019194583A1 (ko) * 2018-04-03 2019-10-10 주식회사 글라세움 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물
KR20200105198A (ko) * 2019-02-28 2020-09-07 주식회사 글라세움 신경계 질환의 예방 또는 치료용 약학적 조성물
KR102692932B1 (ko) 2019-07-30 2024-08-07 주식회사 글라세움 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법
US20250367163A1 (en) 2021-06-08 2025-12-04 Glaceum, Inc. Pharmaceutical composition for preventing or treating degenerative eye diseases
CN113616548B (zh) * 2021-09-02 2023-04-28 河南科技大学 一种水溶性光甘草定包合物及其制备方法
CN119343351A (zh) 2022-04-12 2025-01-21 格拉斯如睦株式会社 用于3-苯基-2,3,4,8,9,10-六氢吡喃并[2,3-f]色烯衍生物的合成方法
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途
KR20240113389A (ko) 2023-01-12 2024-07-22 주식회사 글라세움 퇴행성 골관절염의 예방 또는 치료용 약학적 조성물
KR20250081177A (ko) 2023-11-29 2025-06-05 한국화학연구원 Hsg4112 r형을 유효성분으로 포함하는 반려동물의 비만 예방, 개선 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050035142A (ko) * 2001-10-11 2005-04-15 카네카 코포레이션 페록시좀 증식제 응답성 수용체 리간드제 및 그 제조 방법
KR100565423B1 (ko) * 2003-10-20 2006-03-30 빅 바이오 주식회사 이소플라반 유도체 또는 이소플라벤 유도체의 제조방법
JP2006008604A (ja) * 2004-06-25 2006-01-12 Kuraray Co Ltd イソフラバン誘導体の製造方法
WO2007058480A1 (en) 2005-11-16 2007-05-24 Md Bioalpha Co., Ltd. Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Also Published As

Publication number Publication date
CN105849111A (zh) 2016-08-10
KR102344479B1 (ko) 2021-12-29
PL3098224T3 (pl) 2019-07-31
NZ720328A (en) 2018-02-23
ES2718878T3 (es) 2019-07-05
PT3098224T (pt) 2019-04-26
MX2016008429A (es) 2017-02-23
DK3098224T3 (da) 2019-05-13
CN105849111B (zh) 2018-05-04
HUE043902T2 (hu) 2019-10-28
JP2018135343A (ja) 2018-08-30
BR112016011281B1 (pt) 2021-11-16
AU2014370697B2 (en) 2017-01-19
US9783551B2 (en) 2017-10-10
EP3098224A4 (en) 2017-07-05
US20160272650A1 (en) 2016-09-22
SG11201604371PA (en) 2016-07-28
IL245908B (en) 2020-08-31
EP3098224A1 (en) 2016-11-30
KR20150075030A (ko) 2015-07-02
BR112016011281A2 (enExample) 2017-08-08
MX374944B (es) 2025-03-06
JP2017501163A (ja) 2017-01-12
EP3098224B1 (en) 2019-01-30
CA2929001C (en) 2018-02-20
TW201607949A (zh) 2016-03-01
HRP20190573T1 (hr) 2019-05-17
IL245908A0 (en) 2016-08-02
CY1121554T1 (el) 2020-05-29
AU2014370697A1 (en) 2016-06-16
WO2015099392A1 (ko) 2015-07-02
CA2929001A1 (en) 2015-07-02
TWI585093B (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
JP2018135343A (ja) ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物
JP7036871B2 (ja) 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物
KR20080027191A (ko) 신규한 벤즈옥사졸 유도체, 이의 제조방법 및 이를포함하는 약학 조성물
US20140128418A1 (en) Pyrazole derivatives, preparation method thereof, and composition for preventing and treating osteoporosis containing same
US20210346331A1 (en) Trpv4 activity inhibitor
JP6576445B2 (ja) ファルネシル類の芳香族化合物及びその応用
JP6054102B2 (ja) 一酸化窒素産生促進又は誘導剤
JP5931633B2 (ja) Trpv4活性抑制剤
KR100914213B1 (ko) 고지혈증 및 비만 억제효과를 갖는 조성물
JP5962399B2 (ja) 代謝促進剤組成物
HK1227863A1 (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
TW200529807A (en) Remedy
HK1227863B (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
JP2014028776A (ja) PGC−1α発現促進剤、抗肥満剤及びメタボリックシンドローム予防・治療剤
HK40103109A (en) Composition for treating or preventing obesity or obesity-associated liver disease, comprising verbenone derivatives
HK40004723A (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
HK40004723B (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
JP2016124850A (ja) 抗肥満剤
JP2014101342A (ja) 循環器系疾患の予防・治療に対する新規レスベラトロール2量体の利用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160615

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180323

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180328

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191118

R150 Certificate of patent or registration of utility model

Ref document number: 6620096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250